Christoffer Clemmensen

Shaping the future of cardiometabolic innovation: advances and opportunities - Nature Metabolism Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic...

Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks. www.nature.com/articles/s42...

Shaping the future of cardiometabolic innovation: advances and opportunities Nature Metabolism - Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and...

Unfortunately not up to us to decide on full open access in this case. I hope this link will enable access: rdcu.be/evOFQ Otherwise, I am happy to share a pdf version.

A hypothalamus–brainstem circuit governs the prioritization of safety over essential needs - Nature Neuroscience Animals need to adapt behavior to balance survival with fulfillment of essential needs. Krauth et al. identify neurons in the lateral hypothalamus that, when activated, prioritize survival over other ...

Honored to share that our paper is out today in Nature Neuroscience:

www.nature.com/articles/s41...

We identify a hypothalamic-brainstem circuit linking internal states to locomotion: These projections drive safety-focused movement over competing behavior.

#Neuroscience #Hypothalamus #Locomotion

CBMR spinout Ousia Pharma has secured significant seed funding from the Boston-based venture fund Omega Funds to support the preclinical and clinical development of a once-weekly, dual-incretin-NMDA receptor antagonist conjugate.

cbmr.ku.dk/news/2025/cb...

@clemmensenc.bsky.social

#biotech #glp1

Scarce and unpredictable, yet obesogenic: modeling the impact of food insecurity on adiposity in mice Click on the article title to read more.

Food insecurity drives obesity and adiposity, but how is unclear.
A recent study by @clemmensenc.bsky.social developed a mouse model for this phenomenon lnkd.in/d8pEp2qv
Happy to share a commentary written with @johnspeakman4.bsky.social with our take on that study
doi.org/10.1002/oby....

Incretin-based therapeutics for the treatment of neurodegenerative diseases Neurodegenerative diseases (NDDs) represent a heterogeneous group of disorders characterized by progressive neuronal loss, which results in significant deficits in memory, cognition, motor skills, and sensory functions. As the prevalence of NDDs rises, there is an urgent unmet need for effective therapies. Current drug development approaches primarily target single pathological features of the disease, which could explain the limited efficacy observed in late-stage clinical trials. Originally developed for the treatment of obesity and diabetes, incretin-based therapies, particularly long-acting GLP-1 receptor (GLP-1R) agonists and GLP-1R–gastric inhibitory polypeptide receptor (GIPR) dual agonists, are emerging as promising treatments for NDDs. Despite limited conclusive preclinical evidence, their pleiotropic ability to reduce neuroinflammation, enhance neuronal energy metabolism and promote synaptic plasticity positions them as potential disease-modifying NDD interventions. In anticipation of results from larger clinical trials, continued advances in next-generation incretin mimetics offer the potential for improved brain access and enhanced neuroprotection, paving the way for incretin-based therapies as a future cornerstone in the management of NDDs. This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s disease.

REVIEW | A Vear, MT Heneka and @clemmensenc.bsky.social
( @cbmr.science , @umasschan.bsky.social )

Review on the potential of incretion-based drugs as treatments of neurodegenerative diseases

Incretin-based therapeutics for the treatment of neurodegenerative diseases - Nature Metabolism This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s dise...

Our latest review, led by @anikavear.bsky.social with Michael Heneka, explores the emerging role of incretin-based therapies in neurodegenerative disease treatment www.nature.com/articles/s42...

Food insecurity promotes adiposity in mice Objective The obesity epidemic, driven by a complex interplay of environmental and biological factors, remains a significant global health challenge. Herein, we investigate the impact of food insecu...

🌟 Exciting News! 🌟
I am thrilled to share that my first paper as the first author, Food insecurity promotes adiposity in mice, is now published in #ObesityJournal #ObesitySociety

doi.org/10.1002/oby....

#Foodinsecurity #Obesity #PhD

1/9🧵👇

More strain, more brain: the impact of exercise intensity on neurogenesis Click on the article title to read more.

High-intensity exercise → lactate signaling → neurogenesis? Yes (in some brain areas), but forced treadmill stress might be a potential confounding factor. We unpack this and propose some solutions in our latest JC article in The Journal of Physiology (@jphysiol.bsky.social): doi.org/10.1113/JP28...

𝐋𝐄𝐀𝐏2: 𝐀 𝐧𝐞𝐰 𝐡𝐨𝐫𝐦𝐨𝐧𝐞 𝐰𝐢𝐭𝐡 𝐛𝐢𝐠 𝐢𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐬𝐦?

Research published today in @cp-cellrepmed.bsky.social shows that #insulin and #glucagon play a crucial role in regulating levels of LEAP2 - a newly discovered hormone with promise for treating cardiometabolic disease.

1/

On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in @cp-cellmetabolism.bsky.social covering brain actions of the current and emerging weight loss drugs. @jonaspetersen.bsky.social @johansenvbi.bsky.social

Free access link: authors.elsevier.com/a/1kiaA5WXUlaX…

Pantothenate kinase 4 controls skeletal muscle substrate metabolism - Nature Communications Here, Miranda-Cervantes et al. identified pantothenate kinase 4 (PanK4) as a key regulator of muscle metabolism. Deleting PanK4 impairs fatty acid oxidation and glucose uptake, leading to glucose into...

Curious about muscle metabolism? 🚴‍♂️ We reveal PanK4 as a conserved exercise target in muscle! 💪 PanK4 regulates lipid & glucose use likely via acetyl-CoA. We think PanK4 belongs alongside Akt, mTOR, AMPK, Rac1 & more as a key player in muscle energy homeostasis. #Metabolism #MyoBlue

🙏

GLP-1-directed NMDA receptor antagonism for obesity treatment - Nature Unimolecular integration of NMDA receptor antagonism with GLP-1 receptor agonism effectively reverses obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease.

3/3 In parallel, we developed a strategy to target NMDA receptors in appetite-regulating brain regions using peptide-drug conjugates (PDCs). With the ERC grant, we now aim to advance this work by selectively silencing neurons involved in weight regain.
www.nature.com/articles/s41...

Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment Scaffolding proteins PICK1 and PSD-95 are genetically linked to obesity and therapeutic targets for sustained weight loss.

2/3 Earlier this year we reported that postsynaptic scaffolding proteins interacting with glutamatergic AMPA and NMDA receptors are potential targets for sustained weight loss
www.science.org/doi/10.1126/...

ERC grant funds research to support weight loss maintenance Associate Professor Christoffer Clemmensen from the University of Copenhagen has received an ERC Consolidator Grant for a project that aims to develop new therapeutic interventions that will help peop...

1/3 Kicking off my 🦋 journey with news that my lab has been awarded an ERC Consolidator Grant! Feeling incredibly proud and grateful. The project builds on our long-term focus: homeostatic control of body weight and pharmacological approaches for sustained weight loss. cbmr.ku.dk/news/2024/er...